Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brent Logan

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2025
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic TransplantationStephanie J Lee, Brent Logan, Mary M Horowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2021
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic MalignanciesLeo Luznik, Marcelo C Pasquini, Brent Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2019
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 TrialRichard F Ambinder, Juan Wu, Brent Logan, et al.
Medrxiv : the Preprint Server for Health Sciences|October 7, 2024
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional TrialJason G Dehn, Brent Logan, Bronwen E Shaw, et al.
Transplantation and Cellular Therapy|January 17, 2026
Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trialJoseph Pidala, Brent Logan, Stephanie J Lee, et al.
Transplantation and Cellular Therapy|November 10, 2025
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 TrialJason G Dehn, Brent Logan, Stephanie J Lee, et al.
Transplantation and Cellular Therapy|June 10, 2022
The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical TrialsNosha Farhadfar, Kwang Woo Ahn, Stephanie Bo-Subait, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 4, 2026
IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for Patients with Inborn Errors of Immunity from the Primary Immune Deficiency Treatment Consortium (PIDTC)Danielle E Arnold, Hesham Eissa, Elizabeth Dunn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2023
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401David J Chung, Nina Shah, Juan Wu, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2025
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic TransplantationStephanie J Lee, Brent Logan, Mary M Horowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2021
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic MalignanciesLeo Luznik, Marcelo C Pasquini, Brent Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2019
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 TrialRichard F Ambinder, Juan Wu, Brent Logan, et al.
Medrxiv : the Preprint Server for Health Sciences|October 7, 2024
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional TrialJason G Dehn, Brent Logan, Bronwen E Shaw, et al.
Transplantation and Cellular Therapy|January 17, 2026
Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trialJoseph Pidala, Brent Logan, Stephanie J Lee, et al.
Transplantation and Cellular Therapy|November 10, 2025
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 TrialJason G Dehn, Brent Logan, Stephanie J Lee, et al.
Transplantation and Cellular Therapy|June 10, 2022
The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical TrialsNosha Farhadfar, Kwang Woo Ahn, Stephanie Bo-Subait, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 4, 2026
IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for Patients with Inborn Errors of Immunity from the Primary Immune Deficiency Treatment Consortium (PIDTC)Danielle E Arnold, Hesham Eissa, Elizabeth Dunn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2023
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401David J Chung, Nina Shah, Juan Wu, et al.
Pageof 10